drugset / Trial / NCT03723824

Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

NCT03723824

NaSingle-groupOpen-labelTreatment

Summary

Grazoprevir/elbasvir combination therapy is highly effective in the treatment of genotype 1b chronic hepatitis C, and the drug-drug interaction with central immunosuppressant, such as tacrolimus, should be manageable. The aim of this study is to assess the efficacy and tolerability of grazoprevir/elbasvir combination therapy in treating genotype 1b chronic hepatitis C after liver or kidney transplantation.

Timeline

Start
2019-02-14
Primary completion
2020-11-30
Completion
2021-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Elbasvir Small molecule 50 mg Oral
Subject GRAZOPREVIR ANHYDROUS Small molecule 100 mg Oral